Brevinin-2R and Derivatives as Potential Anticancer Peptides: Synthesis, Purification, Characterization and Biological Activities

  • Robab Hassanvand Jamadi
  • Hashem YaghoubiEmail author
  • Majid Sadeghizadeh


Brevinin-2R (BR-2R), a novel antimicrobial and anti-cancer peptide and two derivatives, BR-C and BR-D, were well designed, synthesized and purified by RP-HPLC (reverse phase high pressure chromatography). Accuracy was confirmed through mass spectrometry. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide) assay was carried out to determine cytotoxicity of various concentrations of peptides and their anti-proliferative potential. Results indicate that these compounds have significant anticancer activities in vitro on both MCF-7 (human breast adenocarcinoma) and A549 (human lung carcinoma) cancer cells in a concentration-dependent manner, although showed less cytotoxicity on human red blood cells. Further investigation verified that apoptosis induction, confirmed by Annexin V/PI staining and strong sub G1 cell cycle arrest, was observed in treated MCF-7 and A549 cells. Induction of apoptosis and anti-proliferating activity were closely associated with augmentation of caspase-3/7 activity, surging the apoptotic cells with no change in caspase-8 activity. The growth inhibition of BR-2R was exceedingly stronger than two derivatives; on the other hand, MCF-7 was more susceptible to treatment than A549. Findings prominently suggested development of Brevinin-2R and derivatives as novel promising compounds for cancer therapy, which may conquer drug resistance.


Anticancer activity Apoptosis Brevinin-2R Cell cycle Chemical synthesis 



This study was financially supported by Islamic Azad University of Ardabil. Authors are grateful to Dr. Hossein Akbari from department of physics at Islamic Azad University, Ardabil Branch and Mehdi Hassanvand Jamadi from Shahid Beheshti University for critically reviewing the manuscript and their invaluable contributions to data analysis.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Informed Consent

Informed consent was obtained from all individual participants included in the study.


  1. Amaral AC, Silva ON, Mundim NC, de Carvalho MJ, Migliolo L, Leite JR, Prates MV, Bocca AL, Franco OL, Felipe MS (2012) Predicting antimicrobial peptides from eukaryotic genomes: in silico strategies to develop antibiotics. Peptides 37:301–308. CrossRefGoogle Scholar
  2. Barras D, Widmann C (2011) Promises of apoptosis-inducing peptides in cancer therapeutics. Curr Pharm Biotechnol 12:1153–1165CrossRefGoogle Scholar
  3. Bohlooli S, Jafari N, Jahed S (2012) Cytotoxic effect of freeze-dried extract of Ecballium elaterium fruit ongastric adenocarcinoma (AGS) and esophageal squamous cell carcinoma (KYSE30) cell lines. J Gastrointest Cancer 43:579–583. CrossRefGoogle Scholar
  4. Brinckerhoff LH, Kalashnikov VV, Thompson LW, Yamshchikov GV, Pierce RA, Galavotti HS, Engelhard VH, Slingluff CL Jr (1999) Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27–35) peptide: implications for peptide vaccines. Int J Cancer 83:326–334CrossRefGoogle Scholar
  5. Brown KL, Hancock RE (2006) Cationic host defense (antimicrobial) peptides. Curr Opin Immunol 18:24–30. CrossRefGoogle Scholar
  6. Coffelt SB, Waterman RS, Florez L, Höner zu Bentrup K, Zwezdaryk KJ, Tomchuck SL, LaMarca HL, Danka ES, Morris CA, Scandurro AB (2008) Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion. Int J Cancer 122:1030–1039. CrossRefGoogle Scholar
  7. Dandekar DS, Lopez M, Carey RI, Lokeshwar BL (2005) Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int J Cancer 115:484–492. CrossRefGoogle Scholar
  8. Dennison SR, Harris F, Phoenix DA (2017) Maximin H5 is an anticancer peptide. Biochimie 137:29–34. CrossRefGoogle Scholar
  9. Eliassen LT, Berge G, Leknessund A, Wikman M, Lindin I, Løkke C, Ponthan F, Johnsen JI, Sveinbjørnsson B, Kogner P, Flaegstad T, Rekdal Ø (2006) The antimicrobial peptide, Lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo. Int J Cancer 119:493–500. CrossRefGoogle Scholar
  10. Evdokiou A, Bouralexis S, Atkins GJ, Chai F, Hay S, Clayer M, Findlay DM (2002) Chemotherapeutic agents sensitize osteogenicsarcoma cells, but not normal human bone cells, to Apo2L/TRAIL induced apoptosis. Int J Cancer 99:491–504. CrossRefGoogle Scholar
  11. Fischer U, Jänicke RU, Schulze-Osthoff K (2003) Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ 10:76–100. CrossRefGoogle Scholar
  12. Gupta SD, Debnath A, Saha A, Giri B, Tripathi G, Vedasiromoni JR, Gomes A, Gomes A (2007) Indian black scorpion (Heterometrus bengalensis Koch) venom induced antiproliferative and apoptogenic activity against human leukemic cell lines U937 and K562. Leuk Res 31:817–825. CrossRefGoogle Scholar
  13. Hazlehurst LA, Landowski TH, Dalton WS (2003) Role of the tumormicroenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Onocogene 22:7396–7402. CrossRefGoogle Scholar
  14. Hilpert K, Fjell CD, Cherkasov A (2008) Short linear cationic antimicrobial peptides: screening, optimizing, and prediction. Methods Mol Biol 494:127–159. CrossRefGoogle Scholar
  15. Hoskin DW, Ramamoorthy A (2008) Studies on anticancer activities of antimicrobial peptides. Biochim Biophys Acta 1778:357–375. CrossRefGoogle Scholar
  16. Kakde D, Jain D, Shrivastava V, Kakde R, Patil AT (2011) Cancer therapeutics-opportunities, challenges and advances in drug delivery. J Appl Pharm Sci 1:1–10Google Scholar
  17. Kibria G, Hatakeyama H, Harashima H (2014) Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system. Arch Pharm Res 37:4–15. CrossRefGoogle Scholar
  18. Lee VH (1988) Enzymatic barriers to peptide and protein absorption. Crit Rev Ther Drug Carrier Syst 5:69–97Google Scholar
  19. Lorenzo HK, Susin SA (2004) Mitochondrial effectors in caspase-independent cell death. FEBS Lett 557:14–20CrossRefGoogle Scholar
  20. Maher S, McClean S (2008) Melittin exhibits necrotic cytotoxicity in gastrointestinal cells which is attenuated by cholesterol. Biochem Pharmacol 75:1104–1114. CrossRefGoogle Scholar
  21. Mann J (2002) Natural products in cancer chemotherapy: past, present and future. Nat Rev Cancer 2:143–148. CrossRefGoogle Scholar
  22. Okun I, Balakin KV, Tkachenko SE, Ivachtchenko AV (2008) Caspase activity modulators as anticancer agents. Anticancer Agents Med Chem 8:322–341CrossRefGoogle Scholar
  23. Papo N, Shai Y (2005) Host defense peptides as new weapons in cancer treatment. Cell Mol Life Sci 62:784–790. CrossRefGoogle Scholar
  24. Pérez-Tomás R (2006) Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 13:1859–1876CrossRefGoogle Scholar
  25. Powell MF, Stewart T, Otvos L Jr, Urge L, Gaeta FC, Sette A, Arrhenius T, Thomson D, Soda K, Colon SM (1993) Peptide stability in drug development. II. Effects of single amino acid substitution and glycosylation on peptide reactivity in human serum. Pharm Res 10:1268–1273CrossRefGoogle Scholar
  26. Ranganath P, Einhorn L, Albany C (2015) Management of chemotherapy induced nausea and vomiting in patients on multiday cisplatin based combination chemotherapy. Biomed Res Int 2015:943618. CrossRefGoogle Scholar
  27. Reddy TS, Reddy VG, Kulhari H, Shukla R, Kamal A, Bansal V (2016) Synthesis of (Z)-1-(1,3-diphenyl-1H-pyrazol-4-yl)-3-(phenylamino) prop-2-en-1-one derivatives as potential anticancer and apoptosis inducing agents. Eur J Med Chem 117:157–166. CrossRefGoogle Scholar
  28. Riedl S, Zweytick D, Lohner K (2011) Membrane-active host defense peptides–challenges and perspectives for the development of novel anticancer drugs. Chem Phys Lipids 164:766–781CrossRefGoogle Scholar
  29. Risso A, Braidot E, Sordano MC, Vianello A, Macrì F, Skerlavaj B, Zanetti M, Gennaro R, Bernardi P (2002) BMAP-28, an antibiotic peptide of innate immunity, induces cell death through opening of the mitochondrial permeability transition pore. Mol Cell Biol 22:1926–1935CrossRefGoogle Scholar
  30. Sah BNP, Vasiljevic T, McKechnie S, Donkor ON (2015) Identification of anticancer peptides from bovine milk proteins and their potential roles in management of cancer: a critical review. Compr Rev Food Sci F 14:123–138. CrossRefGoogle Scholar
  31. Satitmanwiwat S, Changsangfa C, Khanuengthong A, Promthep K, Roytrakul S, Arpornsuwan T, Saikhun K, Sritanaudomchai H (2016) The scorpion venom peptide BmKn2 induces apoptosis in cancerous but not in normal human oral cells. Biomed Pharmacother 84:1042–1050. CrossRefGoogle Scholar
  32. Shibata K, Suzawa T, Soga S, Mizukami T, Yamada K, Hanai N, Yamasaki M (2003) Improvement of biological activity and proteolytic stability of peptides by coupling with a cyclic peptide. Bioorg Med Chem Lett 13:2583–2586CrossRefGoogle Scholar
  33. Sotomayor S, Muñoz-Moreno L, Carmena MJ, Schally AV, Sánchez-Chapado M, Prieto JC, Bajo AM (2010) Regulation of HER expression and transactivation in human prostate cancer cells by atargeted cytotoxic bombesin analog (AN-215) and a bombesin antagonist (RC-3095). Int J Cancer 127:1813–1822. CrossRefGoogle Scholar
  34. Thakur R, Kini S, Kurkalang S, Banerjee A, Chatterjee P, Chanda A, Chatterjee A, Panda D, Mukherjee AK (2016) Mechanism of apoptosis induction in human breast cancer MCF-7 cell by Ruviprase, a small peptide from Daboia russelii russelii venom. Chem Biol Interact 258:297–304. CrossRefGoogle Scholar
  35. Van Brussel JP, Mickisch GH (2003) Multidrug resistance in prostate cancer. Onkologie 26:175–181Google Scholar
  36. Wu M, Hancock RE (1999) Interaction of the cyclic antimicrobial cationic peptide bactenecin with the outer and cytoplasmic membrane. J Biol Chem 274:29–35CrossRefGoogle Scholar
  37. Yang N, Stensen W, Svendsen JS, Rekdal Ø (2002) Enhanced antitumor activity and selectivity of lactoferrin derived peptides. J Pept Res 60:187–197CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2017

Authors and Affiliations

  • Robab Hassanvand Jamadi
    • 1
  • Hashem Yaghoubi
    • 2
    Email author
  • Majid Sadeghizadeh
    • 3
  1. 1.Department of Biology, Faculty of ScienceUniversity of Mohaghegh ArdabiliArdabilIran
  2. 2.Department of Biology, Ardabil BranchIslamic Azad UniversityArdabilIran
  3. 3.Department of Genetics, Faculty of Biological SciencesTarbiat Modares UniversityTehranIran

Personalised recommendations